From the Journals

AHA: Consider obesity as CVD risk factor in children


 

FROM CIRCULATION

The American Heart Association has included obesity and severe obesity in its updated scientific statement outlining risk factors and considerations for cardiovascular risk reduction in high-risk pediatric patients.

The scientific statement is an update to a 2006 American Heart Association (AHA) statement, adding details about obesity as an at-risk condition and severe obesity as a moderate-risk condition. Other additions include classifying type 2 diabetes as a high-risk condition and expanding on new risk factors for cardiovascular disease (CVD) among patients who received treatment for childhood cancer.

The AHA said the statement is aimed at pediatric cardiologists, primary care physicians, and subspecialists who care for at-risk pediatric patients, as well as providers who will care for these patients as they transition to adult life.

Obesity

In the AHA scientific statement, Sarah de Ferranti, MD, MPH, of Boston Children’s Hospital, chair of the writing group, and her colleagues, highlighted a 2016 study that identified a twofold to threefold higher risk of CVD-related mortality among patients who were overweight or obese, compared with patients of normal weight (Diabetes Care. 2016 Nov;39[11]:1996-2003).

Patients with obesity and severe obesity are at increased risk of aortic or coronary fatty streaks, dyslipidemia, high blood pressure, hyperglycemia, and insulin resistance, as well as inflammatory and oxidative stress, the AHA writing group noted.

Pages

Recommended Reading

Carbs vs. fats for CVD
MDedge Hematology and Oncology
Rural pediatric patients face unique cancer care challenges
MDedge Hematology and Oncology
Meta-analysis: IVIG bests anti-D on platelet count in pediatric ITP
MDedge Hematology and Oncology
President Trump calls for end to HIV/AIDS, pediatric cancer
MDedge Hematology and Oncology
PD-1 blockade plus CD19 CAR T boosts CAR T-cell persistence
MDedge Hematology and Oncology
EC approves dasatinib plus chemo for kids with Ph+ ALL
MDedge Hematology and Oncology
Conservatism spreads in prostate cancer
MDedge Hematology and Oncology
Tranexamic acid shows improvements in heavy menstrual bleeding
MDedge Hematology and Oncology
Inhibitor risk nears zero after 75 days in previously untreated hemophilia A
MDedge Hematology and Oncology
Ultrasound method predicts liver complications in pediatric transplant
MDedge Hematology and Oncology